An interventional study of Additional radiation due to imaging in Renal Cell Carcinoma (RCC), sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Carcinoma, Renal Cell with a site in Netherlands — 10 open to participants now, 21 under way, 8 of them phase 3. Carcinoma, Renal Cell · Netherlands.
Among the 105 studies in Carcinoma, Renal Cell with a site in Netherlands, this one is the 65th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 101st registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →10 of the 105 studies in Carcinoma, Renal Cell with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Mark C Burgmans, MD PhD · Sites in Netherlands, France
Ages 18+
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Argentina and 16 more countries
Ages 18+
dr. Tom van der Hulle · Sites in Netherlands
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Netherlands, Austria, Czechia and 1 more country
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 31 · Phase 3 32 · Phase 4 2
First in 1996; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 165 across the 83 interventional studies, 50 across the 21 observational. Of the 76 that completed or were terminated, 28 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 105 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
2 of the studies in Carcinoma, Renal Cell with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT07077161dr. Tom van der HulleCabozantinib Dose Skipping as an Alternative to Dose Reductions | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 105 studies in Carcinoma, Renal Cell with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques
In total 40 patients will be treated for RCC using SBRT.
For 15 patients, additional breath-hold CBCT scans will be made during SBRT to investigate the intra- and inter-fraction uncertainty in breath-hold positions as well as assessing the feasibility of using surface guidance as a surrogate for target position.
Subsequently, 25 patients will be treated using the new motion management technique developed using the extra imaging data obtained from the first cohort of patients. It is hypothesized that either breath-hold or gating in combination with surface guidance will result in a reproducible (stable) position of the target and therefore minimal margins.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written informed consent
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Additional CBCT scans will be made after each fraction, follow-up will be done using photon counting CT
Radiation: Additional radiation due to imaging
Additional imaging will be done using CT, therefore the patient will receive additional radiation dose
Reduction of renal dose
The primary aim of this project is to minimize treatment margins, reducing the PTV, to optimally preserve renal function, while ensuring adequate tumor coverage as well as adhering to dose constraints of OARs. Primary endpoint of this study is the reduction of dose to the healthy ipsilateral kidney, defined as the ipsilateral renal volume receiving 50% of the prescribed dose (V50%).
Time frame: At day 1 planning CTs are acquired for treatment planning. These scans will be used to make a treatment planning with standard motion management and a treatment planning will be made using novel motion management. Both plans will be compared.
Evaluate the current treatment, including the benefit of online adaptive radiotherapy
The possible benefit of online adaptive radiotherapy will be assessed by doing an offline analysis by comparing target coverage in % between adapted and non-adapted, original plans
Time frame: Day 1 planning CTs. Approximately day 14: start radiotherapy (3 times per week). At each fraction: CBCT. At completion of treatment (at approximately day 30) planning for adapted and non-adapted plans
Investigate treatment fraction reduction
the feasibility of transitioning from a 5×8 Gy schedule to 3×14 Gy or 1×26 Gy will be investigated by simulating the difference in the mean number of fractions when using SoC motion management and the novel motion management
Time frame: At day 1 planning CTs are acquired for treatment planning. These will be used for treatment planning for simulated fraction schedules using standard and novel motion management
Change From Baseline in Tumor Contrast Enhancement on Photon-Counting CT
Tumor contrast enhancement measured on contrast-enhanced photon-counting CT scans. Enhancement values will be quantified within the treated lesion and reported as change from baseline.
Time frame: Baseline (pre-treatment) and follow-up at 3, 6, and 12 months after completion of treatment
Change From Baseline in Tumor Iodine Concentration on Photon-Counting CT
Iodine concentration quantified within the treated lesion using material decomposition from contrast-enhanced photon-counting CT scans. Values will be reported as change from baseline.
Time frame: Baseline (pre-treatment) and follow-up at 3, 6, and 12 months after completion of treatment
Monitor side effects
Side-effects are assessed during treatment and follow up, according to Common Terminology Criteria for Adverse Events version 5 (CTC-AE version 5).
Time frame: During treatment and at 3, 6, and 12 months after completion of treatment
Monitor renal function
Renal function changes will be measured using estimated glomerular filtration rate (eGFR)
Time frame: At 3, 6, and 12 months after treatment, followed by biannual evaluations at the referring center (referring urologist) in the second year and annual assessments in the third and fourth years
Started Apr 2026 (actual). Primary completion is estimated for Jan 2030, 45 months after the start.
Of 120 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 114. This study's planned 45 months is close to that.
Counting every sponsor, half of 127 studies reached it within 45 months; a quarter within 21 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.